How to Withdraw Bupropion
For patients on bupropion 300 mg daily, taper to 150 mg once daily before complete discontinuation; for lower doses or monotherapy bupropion (not combination products), abrupt discontinuation is generally safe as bupropion does not cause a classic antidepressant withdrawal syndrome.
Tapering Approach Based on Formulation and Indication
Bupropion Extended-Release (XL) Monotherapy
For patients on 300 mg daily: The FDA-approved label explicitly states to decrease the dose to 150 mg once daily prior to discontinuation 1. This applies to both major depressive disorder and seasonal affective disorder indications.
- Reduce from 300 mg to 150 mg once daily
- Continue 150 mg for a brief period (typically 1-2 weeks, though not specified in labeling)
- Then discontinue completely
For patients on 150 mg daily or lower: The FDA label does not mandate tapering for doses at or below 150 mg 1. Abrupt discontinuation is acceptable.
Naltrexone-Bupropion ER (Contrave) for Obesity
The 2022 AGA guidelines address discontinuation in the context of treatment failure but do not specify a tapering protocol 2. The guidelines state that if patients have not achieved 5% weight loss after 12 weeks on maintenance dose (2 tablets twice daily = 360 mg bupropion + 32 mg naltrexone), the medication should be discontinued as they are likely poor responders 2.
Recommended approach based on FDA guidance for bupropion component:
- From full dose (2 tablets BID): reduce to 1 tablet BID for 1-2 weeks
- Then reduce to 1 tablet daily for 1-2 weeks
- Then discontinue
Bupropion for Smoking Cessation
The NCCN 2016 guidelines recommend 7-12 weeks of therapy with possible extension to 6 months-1 year to promote continued cessation 3. However, these guidelines do not provide specific tapering instructions upon discontinuation.
Apply the same FDA-based approach: If on 300 mg daily (150 mg BID), reduce to 150 mg daily before stopping 1.
Key Clinical Distinctions
Bupropion is Different from Other Antidepressants
Critical point: Unlike SSRIs, SNRIs, and other serotonergic antidepressants, bupropion (a norepinephrine-dopamine reuptake inhibitor) does not typically cause discontinuation syndrome 4, 5. The research literature on antidepressant withdrawal focuses predominantly on serotonergic agents, where gradual hyperbolic tapering over weeks to months may be necessary 5, 6, 7, 8.
Bupropion's pharmacology explains this difference: It lacks serotonergic activity and has a relatively long half-life (approximately 21 hours for the active metabolite), which naturally provides some buffering against abrupt withdrawal effects.
Monitoring During Discontinuation
What to Watch For
While classic withdrawal syndrome is uncommon with bupropion, monitor for:
- Return of depressive symptoms (relapse vs. withdrawal - though withdrawal is unlikely with bupropion)
- Seizure risk changes: Patients may have been on bupropion partly because it was deemed safe for their seizure threshold; ensure no new seizure risk factors emerge 2
- Neuropsychiatric symptoms: Although bupropion carries a black box warning for suicidal thoughts/behaviors (like all antidepressants), monitor for mood changes during discontinuation 3
- Weight changes: If used for obesity management, expect potential weight regain 2
- Smoking relapse: If used for cessation, provide behavioral support 3
Follow-Up Timing
- Week 1-2 after dose reduction: Assess tolerability
- Week 2-4 after complete discontinuation: Assess for relapse of underlying condition
- Ongoing: Monitor based on indication (depression, obesity, smoking)
Special Populations
Hepatic Impairment
Patients with moderate-to-severe hepatic impairment (Child-Pugh 7-15) are already on reduced dosing (150 mg every other day maximum) 1. These patients can likely discontinue without further tapering given the already low dose and extended dosing interval.
Renal Impairment
Patients with renal impairment (GFR <90 mL/min) may already be on reduced dosing 1. Apply the same principle: taper if on 300 mg daily; otherwise discontinuation without taper is acceptable.
Adolescents
The 2025 ATS guideline for adolescent nicotine use suggests bupropion is well-tolerated even at 300 mg daily 9. No specific tapering guidance is provided for this population, suggesting the adult FDA approach is appropriate.
Common Pitfalls to Avoid
Over-tapering: Do not apply SSRI/SNRI hyperbolic tapering protocols to bupropion. The evidence for prolonged, gradual tapers applies to serotonergic antidepressants, not bupropion 4, 5, 6, 7.
Confusing formulations: Ensure you know whether the patient is on immediate-release (IR), sustained-release (SR), or extended-release (XL) bupropion, as well as whether it's monotherapy or combination with naltrexone. The FDA guidance specifically addresses XL formulation 1.
Assuming withdrawal syndrome: If symptoms emerge after bupropion discontinuation, consider relapse of underlying condition (depression, weight gain, smoking) rather than withdrawal syndrome, which is uncommon with this agent.
Abrupt discontinuation from high doses: While bupropion doesn't cause classic withdrawal, the FDA specifically recommends tapering from 300 mg to 150 mg before stopping 1. This may relate to seizure risk management or allowing physiologic adjustment.
When Tapering May Not Be Necessary
- Doses ≤150 mg daily
- Short-term use (<4 weeks)
- Need for urgent discontinuation (e.g., before procedures requiring opiates when on naltrexone-bupropion) 2
- Switching to another antidepressant (cross-taper may be appropriate)